[ad_1]
Our company was invited to join the NVIDIA entrepreneurial program “Inception” and the generative AI platform “BioNeMo™”
REDMOND, Wash., March 11, 2024 (GLOBE NEWSWIRE) — Pattern Computer®, Inc. (“Pattern” or the “Company”) today announced that Chairman and Chief Executive Officer Mark R. Anderson will attend NVIDIA’s GTC 2024 Congress. The flagship conference on artificial intelligence and accelerated computing will be held from March 18 to 21 at the San Jose Convention Center in California, where leaders from across industries will gather to discuss how they chart the path to AI-driven innovation.
During the conference, Pattern will conduct one-on-one meetings with investors and potential partners to present the company’s business and clinical development strategies, recent company achievements and anticipated milestones. To schedule a meeting with Pattern, please contact Denyse Hudson, Pattern’s executive vice president of special projects, at deny@patterncomputer.com.
Pattern was recently invited by the company to join NVIDIA’s Inception program and is now in its top support category. Launched in 2016, the global program provides technical and marketing support to more than 17,000 startups across multiple industries and more than 125 countries. The Inception program helps new startups develop faster through cutting-edge technology and provides opportunities to connect with venture capitalists and access NVIDIA’s latest technology resources. Unlike traditional accelerators, Inception supports all stages of the startup lifecycle.
Additionally, the company was invited to participate in NVIDIA’s BioNeMo™, a generative artificial intelligence platform for drug discovery that simplifies and accelerates the training of proprietary data models, ensuring simple, scalable model deployment for drug discovery applications . BioNeMo provides a fast path to AI model development and deployment, accelerating the AI-driven drug discovery journey.
Mr. Anderson commented, “Pattern uses proprietary pattern discovery technology to perform high-dimensional data analysis in any domain with high data complexity. The result is Pattern’s breakthrough drug discovery with demonstrable value. The BioNeMo framework enables biological Technology and pharmaceutical companies can quickly launch small molecule design capabilities, and the Pattern Discovery Engine™ (PDE) will add value to these capabilities by adding pattern discovery and interpretable AI on top of BioNeMo output. Running on BioNeMo output Partial differential equations will enable the discovery of engineering principles that computational chemists can use to communicate their intuition, generate new hypotheses, and ultimately make discoveries. Additionally, Pattern’s Explainable Artificial Intelligence (TrueXAI™) technology will enable direct exploration Molecular design rules discovered by base models and sub-models within BioNeMo.”
Mr. Anderson added: “2024 will be a critical year for Pattern. Since its inception, Pattern has been on a strategic path with a roadmap focused primarily on R&D and asset generation. We are now at an inflection point from Producing specific high-value assets turns to commercializing them. Over the past eight years, our technology team has been refining these assets, including combinatorial cancer drug discovery and diagnostic advances for the top five cancers, and we hope to partner with companies , the inclusion of these drugs in clinical trials; the Pattern Discovery Engine™; ProSpectral™, a game-changing medical diagnostic tool and research instrumentation; and TrueXAI™.”
About the pattern
Pattern Computer, Inc. is a Seattle-area company that uses its proprietary Pattern Discovery Engine™ to solve the most important and toughest problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in extremely high-order data that cannot be detected by larger systems. While applying its computational platform to challenging areas of drug discovery and diagnostics, the company also enables significant pattern discoveries for partners in other fields, including biotechnology, materials science, aerospace manufacturing, veterinary medicine, aerospace Transportation operations and finance. www.patterncomputer.com.
touch: Laura Galante-Oye (808) 960-2642 – laura@patterncomputer.com
The foregoing contains statements regarding Pattern Computer’s future and is not statements of historical fact. These statements are “forward-looking statements” within the meaning of applicable securities laws and are based on current information and/or management’s good faith belief regarding future events. The words “believe,” “expect,” “anticipate,” “predict,” “should,” “could,” “will” and similar expressions identify forward-looking statements. Forward-looking statements should not be relied upon as guarantees of future performance. By their nature, forward-looking statements involve inherent risks and uncertainties that change over time and actual performance may differ materially from those anticipated in any forward-looking statement. Pattern Computer assumes no obligation to update or revise any forward-looking statements.
Copyright © 2024 Pattern Computer Inc. All rights reserved. Pattern Computer, Inc., Pattern Discovery Engine, PatternBio, TrueXAI™ and ProSpectral are trademarks of Pattern Computer Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.
[ad_2]
Source link